G P Bailey1,2, B Rehman3, K Wind4, D M Wood1,5, R Thanacoody6,7, S Nash8, Jrh Archer1, M Eddleston9, J P Thompson10, J A Vale11, Shl Thomas6,7, P I Dargan1,5. 1. Department of Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 2. Department of Emergency Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK. 3. London Medicines Information Service, London Northwest Healthcare NHS Trust, London, UK. 4. Pharmacy Department, Southend Hospital NHS Trust, Southend, UK. 5. Faculty of Life Sciences and Medicine, King's College London, London, UK. 6. National Poisons Information Service (Newcastle Unit), Newcastle Hospitals NHS Trust, Newcastle, UK. 7. Institute of Cellular Medicine, Newcastle University, Newcastle, UK. 8. Department of Emergency Medicine, Princess Royal University Hospital, London, UK. 9. National Poisons Information Service (Edinburgh Unit), Royal Infirmary of Edinburgh, Edinburgh, UK. 10. National Poisons Information Service (Cardiff Unit), University Hospital Llandough, Cardiff, UK. 11. National Poisons Information Service (Birmingham Unit), City Hospital, Birmingham, UK.
Abstract
BACKGROUND: A 2010/2011 audit of the Royal College of Emergency Medicine (RCEM) National Poisons Information Service (NPIS) UK guidelines on antidote availability demonstrated variable stocking of antidotes for the management of poisoned patients; the guidelines were updated and republished in 2013. AIM: To assess if antidote stocking has improved since the 2010/2011 audit and introduction of the 2013 guidelines. METHODS: Questionnaires were sent to Chief Pharmacists at all 215 acute hospitals in England, Wales and Northern Ireland in October 2014. Data were collected on the timing of availability (category A antidotes should be available immediately, category B within 1 h and category C can be held supraregionally) and stock levels. RESULTS: 169 (78.6%) responses were received. Atropine, calcium gluconate and flumazenil (category A) were the only antidotes available in all hospitals within the recommended time and stock levels. Forty-one (24.3%) hospitals held every category A antidote; this increased to 81 (47.9%) for those holding at least one cyanide antidote and all other category A antidotes. The proportion of hospitals stocking category A/B antidotes within the recommended time increased for 20 (90.9%) category A/B antidotes. Fomepizole (category B) availability increased to 62.1% of hospitals from 11.4% in 2010/2011. Other than penicillamine (63.3% hospitals), there was poor availability (2.4%-36.1%) of category C antidotes. CONCLUSIONS: Availability of category A and B antidotes has improved since the 2010/2011 audit and 2013 guidelines. However, there remains significant variability particularly for category C antidotes. More work is required to ensure that those treating poisoned patients have timely access to antidotes focusing particularly on category C antidotes.
BACKGROUND: A 2010/2011 audit of the Royal College of Emergency Medicine (RCEM) National Poisons Information Service (NPIS) UK guidelines on antidote availability demonstrated variable stocking of antidotes for the management of poisoned patients; the guidelines were updated and republished in 2013. AIM: To assess if antidote stocking has improved since the 2010/2011 audit and introduction of the 2013 guidelines. METHODS: Questionnaires were sent to Chief Pharmacists at all 215 acute hospitals in England, Wales and Northern Ireland in October 2014. Data were collected on the timing of availability (category A antidotes should be available immediately, category B within 1 h and category C can be held supraregionally) and stock levels. RESULTS: 169 (78.6%) responses were received. Atropine, calcium gluconate and flumazenil (category A) were the only antidotes available in all hospitals within the recommended time and stock levels. Forty-one (24.3%) hospitals held every category A antidote; this increased to 81 (47.9%) for those holding at least one cyanide antidote and all other category A antidotes. The proportion of hospitals stocking category A/B antidotes within the recommended time increased for 20 (90.9%) category A/B antidotes. Fomepizole (category B) availability increased to 62.1% of hospitals from 11.4% in 2010/2011. Other than penicillamine (63.3% hospitals), there was poor availability (2.4%-36.1%) of category C antidotes. CONCLUSIONS: Availability of category A and B antidotes has improved since the 2010/2011 audit and 2013 guidelines. However, there remains significant variability particularly for category C antidotes. More work is required to ensure that those treating poisoned patients have timely access to antidotes focusing particularly on category C antidotes.
Authors: Matthew O Wiens; Peter J Zed; Katherine J Lepik; Riyad B Abu-Laban; Jeffrey R Brubacher; Sean K Gorman; Debra A Kent; Roy A Purssell Journal: CJEM Date: 2006-11 Impact factor: 2.410
Authors: Richard C Dart; Stephen W Borron; E Martin Caravati; Daniel J Cobaugh; Steven C Curry; Jay L Falk; Lewis Goldfrank; Susan E Gorman; Stephen Groft; Kennon Heard; Ken Miller; Kent R Olson; Gerald O'Malley; Donna Seger; Steven A Seifert; Marco L A Sivilotti; Tammi Schaeffer; Anthony J Tomassoni; Robert Wise; Gregory M Bogdan; Mohammed Alhelail; Jennie Buchanan; Jason Hoppe; Eric Lavonas; Sara Mlynarchek; Dong-Haur Phua; Sean Rhyee; Shawn Varney; Amy Zosel Journal: Ann Emerg Med Date: 2009-05-05 Impact factor: 5.721
Authors: Ruben H K Thanacoody; Gloria Aldridge; Willie Laing; Paul I Dargan; Stephen Nash; John P Thompson; Allister Vale; Nick Bateman; Simon Thomas Journal: Emerg Med J Date: 2012-08-08 Impact factor: 2.740
Authors: Maryann Mazer-Amirshahi; Kristy L Hawley; Mark Zocchi; Erin Fox; Jesse M Pines; Lewis S Nelson Journal: Clin Toxicol (Phila) Date: 2015-05-08 Impact factor: 4.467
Authors: James T Harnett; Sheena Vithlani; Shabnam Sobhdam; James Kent; Lindsay McClure; Simon Hl Thomas; Paul I Dargan Journal: Eur J Hosp Pharm Date: 2019-07-13